問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Division of Thoracic Medicine

List

156Cases

2018-03-05 - 2021-11-21

Phase I

An Open Label, Phase I Study of BI 754091 Monotherapy and Combination Therapy of BI 754091 and BI 754111 in Asian Patients With Advanced Solid Tumours

  • Condition/Disease

    Advanced solid tumor

  • Test Drug

    BI 754091/BI 754111

Participate Sites
6Sites

Terminated6Sites

2015-05-01 - 2017-03-25

Phase III

A randomized, double-blind, active drug-controlled, parallel grouping trial, in patients with severe to very severe chronic obstructive pulmonary disease (COPD), using tiotropium as a benchmark to evaluate oral inhaled tiotropium + olodaterol fixed-dose combination once a day The effect of 52-week treatment on the acute onset of COPD. [DYNAGITO]

  • Condition/Disease

    COPD

  • Test Drug

    Tiotropium + Olodaterol fixed dose combination (FDC) inhalation solution- RESPIMATR Inhaler

Participate Sites
15Sites

Terminated13Sites

鍾飲文
Kaohsiung Municipal Gangshan Hospital

未分科

鍾啟禮
Taipei Medical University Hospital

Division of Thoracic Medicine

2014-08-08 - 2018-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2007-09-01 - 2009-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2008-10-22 - 2010-10-22

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-03-02 - 2014-08-31

Phase III

LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy

  • Condition/Disease

    Lung cancer

  • Test Drug

    BIBW 2992 (Afatinib)

Participate Sites
8Sites

Terminated8Sites

2011-09-01 - 2013-09-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2010-02-01 - 2011-01-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Terminated13Sites

2015-11-01 - 2017-10-31

Phase III

An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations

  • Condition/Disease

    Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations

  • Test Drug

    ASP8273

Participate Sites
9Sites

Terminated9Sites

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2011-07-01 - 2016-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

1 12 13 14 15 16
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB